A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Weiss, Glen J ^a,b   Byron, Sara A ^b   Aldrich, Jessica ^b   Sangal, Ashish ^a   Barilla, Heather ^a   Kiefer, Jeffrey A ^b,c   Carpten, John D ^b,d   Craig, David W ^b,d   Whitsett, Timothy G ^b,e  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c Systems Oncology   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DASATINIB; ETOPOSIDE; IRINOTECAN; PACLITAXEL; PLATINUM COMPLEX; TEMOZOLOMIDE; TOPOTECAN; PLATINUM; TRANSCRIPTOME; TUMOR PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; EXOME; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; NEXT GENERATION SEQUENCING; PILOT STUDY; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RNA SEQUENCE; SMALL CELL LUNG CANCER; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; BIOPSY; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; MIDDLE AGED; PATHOLOGY; PROCEDURES; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SMALL CELL LUNG CARCINOMA;

ADULT; AGED; BIOPSY; EXOME; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PILOT PROJECTS; PLATINUM; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, RNA; SMALL CELL LUNG CARCINOMA; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 85020194111     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0179170     Document Type: Article

References (26)

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. https://doi.org/10.3322/caac.21387 PMID: 28055103.
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28):4539-44. https://doi.org/10.1200/JCO.2005.04.4859 PMID: 17008692.
3. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, et al. Small cell lung cancer. J Natl Compr Canc Netw. 2013; 11(1):78-98. PMID: 23307984.
4. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999; 17(2):658-67. https://doi.org/10.1200/JCO.1999.17.2.658 PMID: 10080612.
5. Kalemkerian GP. Small Cell Lung Cancer. Semin Respir Crit Care Med. 2016; 37(5):783-96. https://doi.org/10.1055/s-0036-1592116 PMID: 27732999.
6. Tiseo M, Ardizzoni A. Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol. 2007; 2(8):764-72. https://doi.org/10.1097/JTO.0b013e3180986262 PMID: 17762346.
7. von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014; 32(35):4012-9. https://doi.org/10.1200/JCO.2013.54.5392 PMID: 25385727.
8. Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, et al. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC). PLoS One. 2016; 11(1):e0144797. https://doi.org/10.1371/journal.pone.0144797 PMID: 26735301.
9. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. https://doi.org/10.1038/nature13385 PMID: 25079552.
10. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524(7563):47-53. https://doi.org/10.1038/nature14664 PMID: 26168399.
11. Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol. 2017; 241 (4):488-500. https://doi.org/10.1002/path.4853 PMID: 27873319.
12. Karachaliou N, Pilotto S, Lazzari C, Bria E, de Marinis F, Rosell R. Cellular and molecular biology of small cell lung cancer: an overview. Transl Lung Cancer Res. 2016; 5(1):2-15. https://doi.org/10.3978/j.issn.2218-6751.2016.01.02 PMID: 26958489.
13. Mamdani H, Induru R, Jalal SI. Novel therapies in small cell lung cancer. Transl Lung Cancer Res. 2015; 4(5):533-44. https://doi.org/10.3978/j.issn.2218-6751.2015.07.20 PMID: 26629422.
14. Paglialunga L, Salih Z, Ricciuti B, Califano R. Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO Open. 2016; 1(4):e000022. https://doi.org/10.1136/esmoopen-2015-000022 PMID: 27843619.
15. Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-95. https://doi.org/10.1016/S1470-2045(16)30098-5 PMID: 27269741.
16. Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, et al. A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One. 2013; 8(10):e76438. https://doi.org/10.1371/journal.pone.0076438 PMID: 24204627.
17. Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, et al. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res. 2017; 27(4):524-32. https://doi.org/10.1101/gr.213348.116 PMID: 28373299.
18. LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, et al. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. Mol Cancer Ther. 2015; 14(8):1962-71. https://doi.org/10.1158/1535-7163.MCT-15-0153 PMID: 26063764.
19. Nasser S, Kurdolgu AA, Izatt T, Aldrich J, Russell ML, Christoforides A, et al. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine. Pac Symp Biocomput. 2015:56-67. PMID: 25592568.
20. Von Hoff DD, Stephenson JJ Jr., Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010; 28(33):4877-83. https://doi.org/10.1200/JCO.2009.26.5983 PMID: 20921468.
21. Azoury SC, Straughan DM, Shukla V. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety. Curr Cancer Drug Targets. 2015; 15(6):452-62. PMID: 26282545.
22. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17):1974-82. https://doi.org/10.1200/JCO.2014.59.4358 PMID: 25605845.
23. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. https://doi.org/10.1126/science.aaa1348 PMID: 25765070.
24. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-11. https://doi.org/10.1126/science.aad0095 PMID: 26359337.
25. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. https://doi.org/10.1056/NEJMoa1500596 PMID: 26028255.
26. Sloan EA, Ring KL, Willis BC, Modesitt SC, Mills AM. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. Am J Surg Pathol. 2016. https://doi.org/10.1097/PAS.0000000000000783 PMID: 27984238.